Gender-Affirming Hormones Show Distinct Effects on Epigenetic Aging Biomarkers
First study tracking DNA methylation aging clocks during transgender hormone therapy reveals treatment-specific patterns.
Summary
Researchers tracked epigenetic aging biomarkers in 26 transgender individuals during their first year of gender-affirming hormone therapy. While traditional aging clocks remained stable, newer biomarkers showed divergent patterns: trans women on feminizing hormones experienced increased pace of aging and slight telomere gains, while trans men on masculinizing hormones showed stable aging pace but telomere shortening. The study reveals highly individualized responses to treatment, suggesting potential value for personalized monitoring in transgender healthcare.
Detailed Summary
This groundbreaking study represents the first investigation of how gender-affirming hormone therapy affects epigenetic biomarkers of aging and health. Researchers analyzed DNA methylation patterns in 13 trans women and 13 trans men over 12 months of hormone treatment, tracking five key aging biomarkers including traditional epigenetic clocks and newer measures of biological aging.
The cohort showed interesting baseline patterns, with accelerated aging on traditional clocks (particularly among trans men) but healthier profiles on newer biomarkers like PhenoAge and DunedinPACE. This discrepancy may reflect minority stress effects in an otherwise healthy population.
During treatment, traditional aging clocks (Horvath, Hannum, PhenoAge) remained largely unchanged. However, newer biomarkers revealed treatment-specific patterns: trans women on feminizing hormones showed increased DunedinPACE scores (indicating faster aging pace) and slight DNA methylation-based telomere length gains, while trans men on masculinizing hormones exhibited stable to declining aging pace but significant telomere shortening by 12 months.
The most striking finding was the substantial individual variability in responses, suggesting highly personalized biological reactions to hormone therapy. This heterogeneity indicates that epigenetic biomarkers could potentially guide individualized treatment approaches in transgender healthcare.
While these findings provide valuable initial insights into the biological effects of gender-affirming hormones, the small sample size and short follow-up period require cautious interpretation. The research highlights the critical need for larger, longer-term studies to optimize personalized strategies for transgender healthcare and better understand the complex interplay between hormone therapy, stress, and biological aging.
Key Findings
- Traditional epigenetic aging clocks remained stable during first year of hormone therapy
- Trans women showed increased aging pace (DunedinPACE) and slight telomere gains
- Trans men exhibited telomere shortening and stable aging pace
- Substantial individual variability suggests personalized biological responses
- Baseline patterns may reflect minority stress effects in healthy transgender individuals
Methodology
Longitudinal study of 26 transgender individuals (13 trans women, 13 trans men) with blood samples collected at baseline, 6 months, and 12 months. DNA methylation analyzed using Illumina EPIC arrays to compute five aging biomarkers including Horvath, Hannum, PhenoAge clocks, DNAmTL, and DunedinPACE.
Study Limitations
Small sample size (26 participants) and short follow-up period (12 months) limit generalizability. Epigenetic clocks may not perform optimally in transgender populations due to training on different demographics. Longer studies needed to assess clinical significance of observed changes.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.